Press Releases
Published: May 27, 2020

Propeller Health Receives FDA Clearance to Connect Patients Using the Symbicort Inhaler to its Digital Health Platform

The sensor, part of the 510(k) clearance, was developed in partnership with AstraZeneca

MADISON, Wis.–Propeller Health, a leading digital health company dedicated to the management of asthma and COPD, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to connect patients using the Symbicort Inhaler to its digital health platform.

Propeller’s platform already connects to the majority of inhalers used by asthma and COPD patients, including those manufactured by Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion, as well as many generic equivalent inhalers.

Propeller is a digital health tool that helps people with asthma or COPD manage their condition in partnership with their clinician. Propeller sensors attach to patients’ existing inhalers and deliver insights on medication use to the Propeller app on their smartphone, which patients can then share with their clinician to help inform their treatment plan.

The Propeller platform has been shown in previous clinical studies to increase asthma control by up to 63 percent,1 increase medication adherence by up to 58 percent,2 reduce asthma-related emergency department visits and hospitalizations by as much as 57 percent,3 and reduce COPD-related healthcare utilization by as much as 35 percent.4

“Our partnership with AstraZeneca will give respiratory patients a tool to help manage their condition and increase their medication adherence, a critical factor in keeping people out of the hospital,” said David Van Sickle, co-founder and CEO of Propeller Health. “This is an important step in transforming the way people receive preventative care, enabling self-management from home and ensuring that providers have the bandwidth to focus on high-risk patients.”

1 Merchant RK et al. J Allergy Clin Immunol Pract 2016
2 Van Sickle D et al. Eur Respir J 2016
3 Merchant RK et al. World Allergy Org J 2018
4 Alshabani K et al. J Telemed Telecare 2019

You Might Also Like

UC Davis Health collaborates with Propeller Health to improve clinical outcomes of COPD patients
New collaboration will integrate Propeller’s platform with UC Davis Health’s electronic health record system to efficiently provide clinicians data on patient’s disease management (SACRAMENTO, Calif.) — UC Davis Health and Propeller Health have announced a new collaboration that will offer personalized treatment for high-risk patients with asthma and chronic obstructive pulmonary disease (COPD) aiming to […]
Propeller Health Named a Winner of Fierce Healthcare Innovation Awards 2022
Propeller Health’s precision digital health platform wins the Clinical Information Management category of the Fierce Healthcare Innovation Awards 2022. The platform enables physicians and care teams to proactively identify at-risk patients in between routine visits and provide more timely clinical interventions. MADISON, WI, November 15, 2022 – Propeller Health, a leader in precision digital health, […]
Propeller Health accelerates push towards value-based care with new digital health solutions for patients, providers and health systems
Announces integrations with multiple leading Electronic Health Record (EHR) systems, introduces a new solution to enable Remote Therapeutic Monitoring (RTM) by healthcare providers, and launches digital platform updates to enable respiratory care at home, in-clinic, and on-the-go. MIAMI, March 7, 2022 – Propeller Health, a leader in digital health for asthma and chronic obstructive pulmonary […]